If you missed the live session, you can now watch the full webinar on demand.

What you’ll learn:

• A practical overview of the lentiviral production process, from seed train to downstream processing.

• Common bottlenecks that cap LV titers—despite optimal transfection conditions.

• How ProteoNic’s 2G UNic™ technology enhances translational efficiency in host cells to improve LV yield.

• Real-world results and insights from Maurice van der Heijden (ProteoNic) and Diederik Lokhorst (NecstGen).

Whether you’re troubleshooting your own production process or exploring next-gen tools to boost yields and reduce costs, this replay offers valuable technical insights into overcoming a key barrier in gene therapy manufacturing.

If you have additional questions, we invite you to share your questions.

Key areas of focus include:

If you missed our recent webinar on Reducing Lentivirus Costs: A DOE Case Study, you can now watch the replay and gain valuable insights into cost-efficiency strategies for Cell & Gene Therapy manufacturing.

Lentiviral vectors (LV) play a critical role in CAR T therapies, but the high cost of plasmid DNA used in transfection-based production remains a significant challenge. During the webinar, Diederik Lokhorst, Viral Vector Specialist at NecstGen, shared how our team leverages Design of Experiments (DOE) to address this challenge, reduce the Cost of Goods (COG), and make lentivirus-based therapies more affordable.

What You’ll Learn in the Replay:
– An inside look at transfection-based lentivirus production

– ⁠DOE as a tool to understand and improve your manufacturing process

– ⁠A Case study applying DOE to reduce LV Manufacturing Costs for CAR T

If you have additional questions, we invite you to share your questions.